Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor (Q77309925)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740538%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

title

Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740538%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

E A Stein

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740538%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740538%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740538%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

56 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740538%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

25-31; discussion 33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740538%20AND%20SRC:MED&resulttype=core&format=json

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

4 December 2019

cites work

1 reference

12 December 2020

Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II

1 reference

12 December 2020

Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

1 reference

12 December 2020

The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.

1 reference

12 December 2020

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

12 December 2020

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

1 reference

12 December 2020

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

1 reference

12 December 2020

Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020